CytRx Reports Positive Results from Global Phase 2b Clinical Trial with Aldoxorubicin in Advanced Soft Tissue Sarcomas

CytRx

today reported positive results from additional statistical analyses that further support the previously announced highly positive top-line efficacy results from a multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS).